Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Asset Writedowns and Impairment (2023 - 2024)

Taysha Gene Therapies' Asset Writedowns and Impairment history spans 2 years, with the latest figure at $4.8 million for Q3 2024.

  • For Q3 2024, Asset Writedowns and Impairment changed N/A year-over-year to $4.8 million; the TTM value through Sep 2025 reached $5.3 million, changed N/A, while the annual FY2024 figure was $4.8 million, 354.27% up from the prior year.
  • Asset Writedowns and Impairment for Q3 2024 was $4.8 million at Taysha Gene Therapies, up from $449000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $4.8 million in Q3 2024 and bottomed at $449000.0 in Q4 2023.